| Literature DB >> 24156242 |
Vivek Jayaswal1, Sarah-Jane Schramm, Graham J Mann, Marc R Wilkins, Yee Hwa Yang.
Abstract
BACKGROUND: Large-scale molecular interaction networks are dynamic in nature and are of special interest in the analysis of complex diseases, which are characterized by network-level perturbations rather than changes in individual genes/proteins. The methods developed for the identification of differentially expressed genes or gene sets are not suitable for network-level analyses. Consequently, bioinformatics approaches that enable a joint analysis of high-throughput transcriptomics datasets and large-scale molecular interaction networks for identifying perturbed networks are gaining popularity. Typically, these approaches require the sequential application of multiple bioinformatics techniques - ID mapping, network analysis, and network visualization. Here, we present the Variability Analysis in Networks (VAN) software package: a collection of R functions to streamline this bioinformatics analysis.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24156242 PMCID: PMC4015612 DOI: 10.1186/1756-0500-6-430
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Figure 1VAN pipeline for the identification of hubs that are significantly perturbed across biological states.
Figure 2Network module visualization graph generated in R for the melanoma dataset. Network interpretation is greatly aided by visualization. Therefore, VAN provides options to visualise individual hubs of interest (in dark grey) linked to their interaction partners (in light grey) via color-coded, undirected edges that are weighted with the co-expression correlation value for a given state as shown here (see also Additional file 1, VAN User Guide Section 4: Option 1: Visualization in R). In this example, we analysed transcriptomic data in metastatic melanoma [28] in the context of a protein-protein interaction network downloaded from the Human Protein Reference Database [29] (refer to Implementation for details). The hub, CCND2, was one of 81 hubs showing significant (p-value < 0.05) differences in the average gene expression correlation with respect to its interaction partners. The graph on the left hand side of the figure displays the gene expression correlation coefficients determined for patients alive with no sign of relapse (ANSR) more than 4 years after resection of metastatic disease while the graph on the right hand side shows the same for patients who died from melanoma (DM) within 12 months. The colour scale ranges from red (strong negative correlation of expression) through yellow (no correlation) to green (strong positive correlation).
Figure 3Network module visualization graphs generated in Cytoscape for the melanoma dataset. For a global impression of network modules of interest, VAN generates output files that are directly importable into Cytoscape [26], together with a 'color-blind safe’ edge palette file (ExampleVisualStyle.props) and suggested layout protocol (see also Additional file 1, VAN User Guide Section 4: Option 2: Visualization in Cytoscape). As described in Figure 2, we used VAN to analyse gene expression data in metastatic melanoma from Mann et al.[28] in the context of a protein-protein interaction network downloaded from the Human Protein Reference Database [29]. The coordination of gene expression among patients with a survival time greater than four years (Figure 3A) and patients not surviving beyond 12 months (Figure 3B) is affected as indicated by the changes in edge colour. Figures 3C and 3D zoom in on the same subsets of 3A and 3B, respectively and show in more detail the significant (p-value < 0.05) disruption in the coordination of gene co-expression for the hub TRAF1 and its interaction partners. Our example visualisation protocol can be applied to two or more conditions (not shown here) and the Cytoscape platform provides dynamic zooming to allow focus on one, or a few, hubs of interest (C and D).
Cancer Gene Census [27] information for the dysregulated hubs identified in the melanoma cancer dataset
| 0.04 | 0.033 | 0.021 | 0.036 | 0.015 | 0.047 | 0.016 | 0.001 | 0.019 | 0.01 | |
| cyclin D2 | cyclin D3 | Fanconi anemia, complementation group A | Fanconi anemia, complementation group D2 | GATA binding protein 2 | kinesin family member 5B | LIM domain only 2 (rhombotin-like 1) (RBTN2) | ret proto-oncogene | von Hippel-Lindau syndrome gene | Wiskott-Aldrich syndrome | |
| 894 | 896 | 2175 | 2177 | 2624 | 3799 | 4005 | 5979 | 7428 | 7454 | |
| 12 | 6 | 16 | 3 | 3 | 10 | 11 | 10 | 3 | X | |
| 12p13 | 6p21 | 16q24.3 | 3p26 | 3q21.3 | 10p11.22 | 11p13 | 10q11.2 | 3p25 | Xp11.23-p11.22 | |
| yes | yes | NA | NA | yes | yes | yes | yes | yes | NA | |
| NA | NA | yes | yes | NA | NA | NA | yes | yes | NA | |
| NHL,CLL | MM | NA | NA | AML(CML blast transformation) | NSCLC | T-ALL | medullary thyroid, papillary thyroid, pheochromocytoma, NSCLC | renal, hemangioma, pheochromocytoma | NA | |
| NA | NA | AML, leukemia | AML, leukemia | NA | NA | NA | medullary thyroid, papillary thyroid, pheochromocytoma | renal, hemangioma, pheochromocytoma | lymphoma | |
| NA | NA | Fanconi anaemia A | Fanconi anaemia D2 | NA | NA | NA | Multiple endocrine neoplasia 2A/2B | von Hippel-Lindau syndrome | Wiskott-Aldrich syndrome | |
| L | L | L | L | L | E | L | E, O | E, M, O | L | |
| Dom | Dom | Rec | Rec | Dom | Dom | Dom | Dom | Rec | X-linked recessive | |
| T | T | D, Mis, N, F, S | D, Mis, N, F | Mis | T | T | T, Mis, N, F | D, Mis, N, F, S | Mis, N, F, S | |
| IGL@ | IGH@ | NA | NA | NA | RET, ALK | TRD@ | H4, PRKAR1A, NCOA4, PCM1, GOLGA5, TRIM33, KTN1, TRIM27, HOOK3, KIF5B, CCDC6 | NA | NA | |
| NA | NA | NA | NA | NA | NA | NA | yes | NA | NA | |
| NA | NA | NA | NA | NA | NA | NA | Hirschsprung disease | NA | NA |
^Abbreviations: AML; acute myelogenous leukemia, CLL; chronic lymphatic leukemia, CML; chronic myeloid leukemia, D; large deletion, Dom; dominant, E; epithelial, F; frameshift, L; leukaemia/lymphoma, M; mesenchymal, Mis; Missense, MM; multiple myeloma, N; nonsense, NHL; non-Hodgkin lymphoma, NSCLC; non small cell lung cancer, O; other, Rec; reccesive, S; splice site, T; translocation, T-ALL; T-cell acute lymphoblastic leukemia, Chr; Chromosome, Mut; Mutation, NA; No data or not applicable.